News & Events about Genmab A S.
Company Announcement COPENHAGEN, Denmark; April 24, 2023 Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with Janssen Biotech, Inc. for daratumumab. The review of the ...
Genmabandargenxhave entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands 04/17/2023 argenx SE (Euronext & Nasdaq: ARGX) and...
Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmabandargenxhave entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapiesDiscovery programs against two differentiated targets are underway GenmabA/S(Nasdaq:GMAB) andargenx(...
Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic...
Globe Newswire
2 months ago
Company Announcement COPENHAGEN, Denmark; April 3, 2023 Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 31, 2023. On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Unit...